The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Open accessAbstract
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus meeting was held among the study neurologists and neuropsychologists to clinically determine each potential participant’s cognitive status grouping (NC, MCI, or dementia) based on a standardized approach used in National Institute of Health (NIH)-funded Alzheimer’s Disease Centers across the United States (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
From Internet-Based Conversational Engagement Randomized Controlled Clinical Trial (I-CONECT) Among Socially Isolated Adults 75+ Years Old With Normal Cognition or Mild Cognitive Impairment: Topline Results (2024) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the atrophy of specific brain regions shown by structural MRI is an important part of the diagnostic criteria for FTD and AD (McKhann et al., 2011; Rascovsky et al., 2011)”
From Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease (2021) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diagnosis of AD was made in accordance with the NINCDS-ADRCA criteria (McKhann et al., 2011) and MCI was diagnosed according to the Mayo criteria (Petersen et al., 1999).”
From Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction (2018) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During this extended preclinical period prior to the dementia diagnosis, many patients develop behavioral or neuropsychiatric changes, including agitation, irritability, decreased motivation, loss of empathy, and depression, which increase the risk of transition to mild cognitive impairment and AD.12-14”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“All patients (n = 96) were clinically evaluated by expert neurologists (M.G., D.J.I.) at the time of recording at the frontotemporal degeneration center (FTDC) in the neurology department of the Hospital of the University of Pennsylvania, and they were classified at a weekly consensus meeting at the FTDC using established clinical criteria.”
From Automatic classification of AD pathology in FTD phenotypes using natural speech (2024) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“AD is clinically diagnosed using the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria [5].”
From Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Probable AD diagnoses were assigned according to both NINCDS/ADRDA criteria (23), and the core clinical NIA-AA criteria (28).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [28]
In the citing paper
“The University of California San Francisco (UCSF) Memory and Aging Center Dementia cohort consisted of 152 carefully phenotyped older adults meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for either mild-cognitive impairment22 or probable dementia because of AD.23”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [23]
In the citing paper
“More recently, the imaging of amyloid with compounds such as the radiolabeled Pittsburgh compound B (11C-PiB) has received much interest and been proposed as a biomarker of AD.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“These, along with amyloid imaging using positron emission tomography (PET), may help determine AD as the main or contributory cause of the cognitive disorder.”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“CSF markers for AD are, however, better developed, with lower levels of Aβ42 and elevated levels of tau/phosphorylated-tau being indicative of AD pathology.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“The clinical criteria used most commonly are the NIA‐AA criteria for dementia 89 and mild cognitive impairment 90 due to Alzheimer's disease.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [89]
In the citing paper
“The development of the DSM-5 criteria for the various subtypes involved extensive discussions with experts from diverse fields to harmonize the DSM criteria with criteria developed by other expert groups, such as the NIA-AA, 20,27 the frontotemporal dementia expert group, 28,29 the consortium on DLB, 30 the VASCOG working group, 31 the Movement Disorder Study Task Force on Parkinson Disease 32 and”
From Classifying neurocognitive disorders: the DSM-5 approach (2014) · cites this paper as [27]
In the citing paper
“This different pattern of results in bvFTD and AD may reflect the preferential and widespread damage within the AIN in bvFTD11,14,16, 17, 18, 19, 20,24 whereas in AD, AIN damage appears to be more circumscribed.17,38,88”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“Second, patients received diagnoses based on established clinical criteria only,37,38 without testing for ATN biomarkers in AD such as the deposition of amyloid-β and tau proteins established via Positron Emission Tomography, CSF, or plasma in AD.94, 95, 96, 97”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“The diagnosis was concluded in a multidisciplinary meeting using consensus criteria for probable FTD, PPD (DSM-V), and AD [25,31,32].”
In the citing paper
“Detection of abnormal Aβ accumulation (Aβ positivity) may support the clinical diagnosis of AD1,2 and is essential for including participants in clinical AD trials targeting Aβ.3”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [2]
In the citing paper
“Diagnosis was established by the multidisciplinary teams at each research institute based on current consensus diagnostic criteria (McKhann et al., 2011; Postuma et al., 2015; Rascovsky et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“AD patients present with predominant episodic memory loss and impaired executive functioning, with atrophy observed in the medial temporal lobe, most notably in the hippocampus and posterior cingulate (McKhann et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“A diagnosis of probable AD had been made prior to the study by neurologists at the Memory Center according to the clinical criteria of the National Institute on Aging and the Alzheimer’s Association criteria for probable AD [1].”
From The effects of confinement on neuropsychiatric symptoms in Alzheimer's disease during the COVID-19 crisis (2020) · cites this paper as [1]
In the citing paper
“The 3 major clinical criteria for the AD spectrum are the revised 2011 NIA-AA criteria, 32,39 the International Working Group (Dubois and colleagues 39,40 ) 2010 revised new lexicon criteria, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.41”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for AD recognizes nonamnestic AD presentations that include language, visuospatial, and executive dysfunction features.32”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“dementia-level impairment requires cognitive or behavioral symptoms”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“MCI diagnosis is a matter of”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“With the advent of biomarkers that enable in vivo identification of underlying AD pathological conditions, and the acceptance that AD begins years before the emergence of cognitive impairment, AD is now commonly accepted as a clinicopathological entity7,8 that can be diagnosed without histopathological examination, in the presence of appropriate biomarker evidence of an underlying condition.6,8,9”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 7×
“Initial efforts to incorporate biomarkers into the diagnosis of AD dementia and MCI [14] need to be coupled with a more comprehensive approach to the diagnostic process.”
BackgroundInfluentialSelf-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“For example, Dementia with Lewy bodies [8], vascular dementia [9], behavior variant frontotemporal dementia [10–12], and primary progressive aphasia [13] have been characterized extensively.”
BackgroundSelf-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“It should be noted that the clinical syndrome, as summarized in this section and Table 1, is almost identical to the one previously described by Petersen et al [5,6,11].”
ResultSelf-citationRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · cited 1×
“For example, Dementia with Lewy bodies [8], vascular dementia [9], behavior variant frontotemporal dementia [10–12], and primary progressive aphasia [13] have been characterized extensively.”
Background
Cited by
Sorted by citations
Items 1,101–1,200 of 1,532
Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2012-121471 · Cited by 105
Chang, L. Y. L., Lowe, J., Ardiles, A., Lim, J., Grey, A. C., Robertson, K., Danesh‐Meyer, H., Palacios, A. G., & Acosta, M. L. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.06.004 · Cited by 106
Alzheimer disease pathology and the cerebrospinal fluid proteome
Dayon, L., Núñez Galindo, A., Wojcik, J., Cominetti, O., Corthésy, J., Oikonomidi, A., Henry, H., Kussmann, M., Migliavacca, E., Severin, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0397-4 · Cited by 101
Huggins, C. J., Escudero, J., Parra, M. A., Scally, B., Anghinah, R., Vitória Lacerda De Araújo, A., Basile, L. F., & Abasolo, D. (2021) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac05d8 · Cited by 105
Anti‐amyloid antibody treatments for Alzheimer's disease
Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16049 · Cited by 106
A critical review of chronic traumatic encephalopathy
Iverson, G. L., Gardner, A. J., McCrory, P., Zafonte, R., & Castellani, R. J. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.008 · Cited by 103
Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease
Battista, P., Salvatore, C., Berlingeri, M., Cerasa, A., & Castiglioni, I. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.04.026 · Cited by 98
Randolph, C., Karantzoulis, S., & Guskiewicz, K. (2013) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617713000805 · Cited by 103
Möller, C., Pijnenburg, Y. A. L., van der Flier, W. M., Versteeg, A., Tijms, B., de Munck, J. C., Hafkemeijer, A., Rombouts, S. A. R. B., van der Grond, J., van Swieten, J., et al. (2016) · Radiology · doi:10.1148/radiol.2015150220 · Cited by 103
Self-citationShigemizu, D., Mori, T., Akiyama, S., Higaki, S., Watanabe, H., Sakurai, T., Niida, S., & Ozaki, K. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00654-x · Cited by 103
PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
ApoE influences regional white-matter axonal density loss in Alzheimer's disease
Slattery, C. F., Zhang, J., Paterson, R. W., Foulkes, A. J. M., Carton, A., Macpherson, K., Mancini, L., Thomas, D. L., Modat, M., Toussaint, N., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.021 · Cited by 102
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Lower practice effects as a marker of cognitive performance and dementia risk: a literature review
Jutten, R. J., Grandoit, E., Foldi, N. S., Sikkes, S. A. M., Jones, R. N., Choi, S., Lamar, M. L., Louden, D. K. N., Rich, J., Tommet, D., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12055 · Cited by 102
Cascaded multi-modal mixing transformers for Alzheimer’s disease classification with incomplete data
Liu, L., Liu, S., Zhang, L., To, X. V., Nasrallah, F., & Chandra, S. S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120267 · Cited by 101
Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions
Gavett, B. E., Cantu, R. C., Shenton, M., Lin, A. P., Nowinski, C. J., McKee, A. C., & Stern, R. A. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834cd477 · Cited by 101
Collins, R. N., & Kishita, N. (2019) · The Gerontologist · doi:10.1093/geront/gny024 · Cited by 101
Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Walker, Z., Morgan, R., Hinz, R., Biju, M., Kuruvilla, T., Brooks, D. J., et al. (2018) · Brain · doi:10.1093/brain/awy188 · Cited by 270
Oxidative Stress and Gut-Derived Lipopolysaccharides in Neurodegenerative Disease: Role of NOX2
Loffredo, L., Ettorre, E., Zicari, A. M., Inghilleri, M., Nocella, C., Perri, L., Spalice, A., Fossati, C., De Lucia, M. C., Pigozzi, F., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8630275 · Cited by 100
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Kim, J. P., Kim, J., Park, Y. H., Park, S. B., Lee, J. S., Yoo, S., Kim, E.-J., Kim, H. J., Na, D. L., Brown, J. A., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101811 · Cited by 100
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
Self-citationKoch, K., Myers, N. E., Göttler, J., Pasquini, L., Grimmer, T., Förster, S., Manoliu, A., Neitzel, J., Kurz, A., Förstl, H., et al. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhu151 · Cited by 97
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“The latter set is for use in three circumstances: investigational use, clinical trials (Section 5), and as optional clinical tools for use where available and when deemed appropriate by the clinician (McKhann et al., 2011).”
BackgroundMethodThal, D. R., Attems, J., & Ewers, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141461 · Cited by 100
ABCA7 frameshift deletion associated with Alzheimer disease in African Americans
Cukier, H. N., Kunkle, B. W., Vardarajan, B. N., Rolati, S., Hamilton-Nelson, K. L., Kohli, M. A., Whitehead, P. L., Dombroski, B. A., Van Booven, D., Lang, R., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000079 · Cited by 100
Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers
Rózga, M., Bittner, T., Batrla, R., & Karl, J. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.02.002 · Cited by 99
Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93
Fernández-Blázquez, M. A., Ávila-Villanueva, M., Maestú, F., & Medina, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150956 · Cited by 98
Weise, C. M., Chen, K., Chen, Y., Kuang, X., Savage, C. R., & Reiman, E. M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.07.016 · Cited by 96
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
“As the disease progresses, preclinical AD transits to mild cognitive impairment (MCI) in which cognition deficits do not affect patients’ performance at work or regular daily activities, but eventually may develop into AD (McKhann et al. 2011; Saido 2013).”
BackgroundMolecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment
Knezevic, D., & Mizrahi, R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.007 · Cited by 97
Tracking the progression of social cognition in neurodegenerative disorders
Kumfor, F., Irish, M., Leyton, C., Miller, L., Lah, S., Devenney, E., Hodges, J. R., & Piguet, O. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307098 · Cited by 97
White matter alterations in early‐stage Alzheimer's disease: A tract‐specific study
Wen, Q., Mustafi, S. M., Li, J., Risacher, S. L., Tallman, E., Brown, S. A., West, J. D., Harezlak, J., Farlow, M. R., Unverzagt, F. W., et al. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.06.003 · Cited by 96
Amini, N., Ibn Hach, M., Lapauw, L., Dupont, J., Vercauteren, L., Verschueren, S., Tournoy, J., & Gielen, E. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13485 · Cited by 95
Clark, C., Lewczuk, P., Kornhuber, J., Richiardi, J., Maréchal, B., Karikari, T. K., Blennow, K., Zetterberg, H., & Popp, J. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00805-8 · Cited by 88
Bron, E. E., Steketee, R. M. E., Houston, G. C., Oliver, R. A., Achterberg, H. C., Loog, M., van Swieten, J. C., Hammers, A., Niessen, W. J., Smits, M., et al. (2014) · Human Brain Mapping · doi:10.1002/hbm.22522 · Cited by 93
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases
Cummings, J. (2021) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.07.011 · Cited by 96
Sex differences in the genetic predictors of Alzheimer’s pathology
Dumitrescu, L., Barnes, L. L., Thambisetty, M., Beecham, G., Kunkle, B., Bush, W. S., Gifford, K. A., Chibnik, L. B., Mukherjee, S., De Jager, P. L., et al. (2019) · Brain · doi:10.1093/brain/awz206 · Cited by 93
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Sunaert, S., Lemmens, R., Triau, E., Emsell, L., Vandenbulcke, M., & Van Laere, K. (2020) · Neurology · doi:10.1212/wnl.0000000000009818 · Cited by 88
Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study
Cho, H., Choi, J. Y., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., Jack, C. R., & Lyoo, C. H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221697 · Cited by 94
Self-citationLarouche, E., Hudon, C., & Goulet, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.058 · Cited by 93
Oeckl, P., Anderl-Straub, S., Von Arnim, C. A. F., Baldeiras, I., Diehl-Schmid, J., Grimmer, T., Halbgebauer, S., Kort, A. M., Lima, M., Marques, T. M., et al. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328547 · Cited by 94
Current understanding of chronic traumatic encephalopathy
Baugh, C. M., Robbins, C. A., Stern, R. A., & McKee, A. C. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0306-5 · Cited by 94
Vision function abnormalities in Alzheimer disease
Tzekov, R., & Mullan, M. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.10.002 · Cited by 94
Rossini, P. M., Miraglia, F., & Vecchio, F. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12645 · Cited by 93
An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease
On Behalf of the BELNEU Consortium, De Roeck, A., Duchateau, L., Van Dongen, J., Cacace, R., Bjerke, M., Van den Bossche, T., Cras, P., Vandenberghe, R., De Deyn, P. P., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1841-z · Cited by 93
Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13164 · Cited by 92
Staffaroni, A., Elahi, F., McDermott, D., Marton, K., Karageorgiou, E., Sacco, S., Paoletti, M., Caverzasi, E., Hess, C., Rosen, H., et al. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1608808 · Cited by 91
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
Stokes, A. C., Weiss, J., Lundberg, D. J., Xie, W., Kim, J. K., Preston, S. H., & Crimmins, E. M. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2831 · Cited by 94
Vijverberg, E. G. B., Wattjes, M. P., Dols, A., Krudop, W. A., Möller, C., Peters, A., Kerssens, C. J., Gossink, F., Prins, N. D., Stek, M. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160285 · Cited by 92
Self-citationRamanan, S., Bertoux, M., Flanagan, E., Irish, M., Piguet, O., Hodges, J. R., & Hornberger, M. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000837 · Cited by 90
Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium
Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L. K., Heuer, H. W., Knopman, D., Kornak, J., Boxer, A., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.05.013 · Cited by 92
Self-citationThe dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
Phenotypic heterogeneity in dementia: a challenge for epidemiology and biomarker studies
Ryan, J., Fransquet, P., Wrigglesworth, J., & Lacaze, P. (2018) · Frontiers in Public Health · doi:10.3389/fpubh.2018.00181 · Cited by 91
In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer’s disease
Serra, L., D'Amelio, M., Di Domenico, C., Dipasquale, O., Marra, C., Mercuri, N. B., Caltagirone, C., Cercignani, M., & Bozzali, M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.012 · Cited by 91
Pijnenburg, Y. A. L., Verwey, N. A., van der Flier, W. M., Scheltens, P., & Teunissen, C. E. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.001 · Cited by 91
Self-citationTherriault, J., Pascoal, T. A., Benedet, A. L., Tissot, C., Savard, M., Chamoun, M., Lussier, F., Kang, M. S., Berzgin, G., Wang, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011416 · Cited by 91
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Bertens, D., Tijms, B. M., Scheltens, P., Teunissen, C. E., & Visser, P. J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0233-7 · Cited by 91
Self-citationNeuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
Self-citationVecchio, F., Miraglia, F., Iberite, F., Lacidogna, G., Guglielmi, V., Marra, C., Pasqualetti, P., Tiziano, F. D., & Rossini, P. M. (2018) · Annals of Neurology · doi:10.1002/ana.25289 · Cited by 89
Femminella, G. D., Ninan, S., Atkinson, R., Fan, Z., Brooks, D. J., & Edison, P. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150827 · Cited by 88
Nobukawa, S., Yamanishi, T., Kasakawa, S., Nishimura, H., Kikuchi, M., & Takahashi, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00255 · Cited by 89
Lau, K. M., Parikh, M., Harvey, D. J., Huang, C.-J., & Farias, S. T. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000818 · Cited by 89
Feelings Without Memory in Alzheimer Disease
Guzmán-Vélez, E., Feinstein, J. S., & Tranel, D. (2014) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000020 · Cited by 88
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04496-0 · Cited by 88
Mattsson, N., Groot, C., Jansen, W. J., Landau, S. M., Villemagne, V. L., Engelborghs, S., Mintun, M. M., Lleo, A., Molinuevo, J. L., Jagust, W. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.009 · Cited by 88
Self-citationXu, J., Begley, P., Church, S. J., Patassini, S., McHarg, S., Kureishy, N., Hollywood, K. A., Waldvogel, H. J., Liu, H., Zhang, S., et al. (2016) · Scientific Reports · doi:10.1038/srep27524 · Cited by 85
Myelin changes at the early stage of 5XFAD mice
Gu, L., Wu, D., Tang, X., Qi, X., Li, X., Bai, F., Chen, X., Ren, Q., & Zhang, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.013 · Cited by 87
The Fornix in Mild Cognitive Impairment and Alzheimer’s Disease
Nowrangi, M. A., & Rosenberg, P. B. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00001 · Cited by 87
Frederiksen, K. S., Gjerum, L., Waldemar, G., & Hasselbalch, S. G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170567 · Cited by 86
Speech- and language-based classification of Alzheimer's disease: a systematic review
Vigo, I., Coelho, L., & Reis, S. (2022) · Bioengineering · doi:10.3390/bioengineering9010027 · Cited by 83
Adluru, N., Destiche, D. J., Lu, S. Y.-F., Doran, S. T., Birdsill, A. C., Melah, K. E., Okonkwo, O. C., Alexander, A. L., Dowling, N. M., Johnson, S. C., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.04.008 · Cited by 85
Advancing Alzheimer’s research: a review of big data promises
Zhang, R., Simon, G., & Yu, F. (2017) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2017.07.002 · Cited by 77
Stylianou, M., Murphy, N., Peraza, L. R., Graziadio, S., Cromarty, R., Killen, A., O' Brien, J. T., Thomas, A. J., LeBeau, F. E. N., & Taylor, J.-P. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.03.013 · Cited by 79
Physical Activity and Alzheimer’s Disease: A Systematic Review
Stephen, R., Hongisto, K., Solomon, A., & Lönnroos, E. (2017) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw251 · Cited by 262
More than words: social cognition across variants of primary progressive aphasia
Fittipaldi, S., Ibanez, A., Baez, S., Manes, F., Sedeno, L., & Garcia, A. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.020 · Cited by 82
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers
La, A. L., Walsh, C. M., Neylan, T. C., Vossel, K. A., Yaffe, K., Krystal, A. D., Miller, B. L., & Karageorgiou, E. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181145 · Cited by 83
Functional alterations of myeloid cells during the course of Alzheimer’s disease
Thome, A. D., Faridar, A., Beers, D. R., Thonhoff, J. R., Zhao, W., Wen, S., Pascual, B., Masdeu, J. C., & Appel, S. H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0293-1 · Cited by 83
Teipel, S. J., the EDSD study group, Grothe, M. J., Filippi, M., Fellgiebel, A., Dyrba, M., Frisoni, G. B., Meindl, T., Bokde, A. L. W., Hampel, H., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131829 · Cited by 82
The SHARE program for dementia: Implementation of an early-stage dyadic care-planning intervention.
Orsulic-Jeras, S., Whitlatch, C. J., Szabo, S. M., Shelton, E. G., & Johnson, J. (2019) · Dementia · doi:10.1177/1471301216673455 · Cited by 82
Begcevic, I., Brinc, D., Brown, M., Martinez-Morillo, E., Goldhardt, O., Grimmer, T., Magdolen, V., Batruch, I., & Diamandis, E. P. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.027 · Cited by 81
Parke, B., Hunter, K. F., Strain, L. A., Marck, P. B., Waugh, E. H., & McClelland, A. J. (2013) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2012.11.005 · Cited by 81
APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
Ferrari-Souza, J. P., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Bellaver, B., Ferreira, P. C. L., Malpetti, M., Wang, Y.-T., Povala, G., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1474 · Cited by 81
Self-citationKynurenic Acid Levels are Increased in the CSF of Alzheimer’s Disease Patients
González-Sánchez, M., Jiménez, J., Narváez, A., Antequera, D., Llamas-Velasco, S., Martín, A. H.-S., Molina Arjona, J. A., López de Munain, A., Lleó Bisa, A., Marco, M.-P., et al. (2020) · Biomolecules · doi:10.3390/biom10040571 · Cited by 84
Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77
Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
Self-citationShigemizu, D., Mitsumori, R., Akiyama, S., Miyashita, A., Morizono, T., Higaki, S., Asanomi, Y., Hara, N., Tamiya, G., Kinoshita, K., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01272-3 · Cited by 80
Tu, S., Spiers, H. J., Hodges, J. R., Piguet, O., & Hornberger, M. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160592 · Cited by 70
Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns
Pålhaugen, L., Sudre, C. H., Tecelao, S., Nakling, A., Almdahl, I. S., Kalheim, L. F., Cardoso, M. J., Johnsen, S. H., Rongve, A., Aarsland, D., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20957604 · Cited by 79
Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18.
Devous, M. D., Joshi, A. D., Navitsky, M., Southekal, S., Pontecorvo, M. J., Shen, H., Lu, M., Shankle, W. R., Seibyl, J. P., Marek, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200691 · Cited by 79
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Prevalence of cortical superficial siderosis in a memory clinic population
Zonneveld, H. I., Goos, J. D. C., Wattjes, M. P., Prins, N. D., Scheltens, P., van der Flier, W. M., Kuijer, J. P. A., Muller, M., & Barkhof, F. (2014) · Neurology · doi:10.1212/wnl.0000000000000150 · Cited by 78
Self-citationAltered gut microbiota in adults with subjective cognitive decline: the SILCODE study
Sheng, C., Lin, L., Lin, H., Wang, X., Han, Y., & Liu, S.-L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210259 · Cited by 78
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
Identification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
Casaletto, K. B., Rentería, M. A., Pa, J., Tom, S. E., Harrati, A., Armstrong, N. M., Rajan, K. B., Mungas, D., Walters, S., Kramer, J., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-191114 · Cited by 78
Lalli, M. A., Bettcher, B. M., Arcila, M. L., Garcia, G., Guzman, C., Madrigal, L., Ramirez, L., Acosta-Uribe, J., Baena, A., Wojta, K. J., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.131 · Cited by 73
Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77
Metadata
- Authors
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H.
- Affiliations
- Johns Hopkins University (US)
- Mayo Clinic (US)
- Lady Davis Institute for Medical Research (CA)
- Harvard University (US)
- University of California, Irvine (US)
- University of Pittsburgh (US)
- National Institute of Neurological Disorders and Stroke (US)
- Columbia University Irving Medical Center (US)
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- UCL Queen Square Institute of Neurology (GB)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- Department of Psychiatry Northwestern Feinberg School of Medicine Chicago IL USA
- National Institutes of Health (US)
- Corresponding author
- McKhann, Guy M.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 263-269
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3312024
- OpenAlex
- W2115017507
- Semantic Scholar
- 37d2d04f8c09da1f0cf8434a38a51841b5b703bf
- Cited by
- 18,657
- References
- 44
- Citations by year
- 2026: 893 · 2025: 1313 · 2024: 1585 · 2023: 1543 · 2022: 1670 · 2021: 1796 · 2020: 1602 · 2019: 1448 · 2018: 1297 · 2017: 1200 · 2016: 1088 · 2015: 1062 · 2014: 794 · 2013: 715 · 2012: 491
- FWCI
- 471.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute on Aging
- Forest Pharmaceuticals
- Alzheimer's Association
- Fidelity Biosciences
- Baxter International
- Pfizer
- Johnson and Johnson
- Avid Radiopharmaceuticals
- GE Healthcare
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, dementia diagnosis
- MeSH terms
- Alzheimer Disease, Diagnosis, Differential, Diagnostic Imaging, Humans, Societies, Medical, United States, Biomarkers, Practice Guidelines as Topic, Disease Progression, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
